|会社名||Amgen In （アムジェン）|
|分野（sector）||Health Care ヘルスケア|
|産業（industry）||Biotechnology: Biological Products (No Diagnostic Substances)|
|業種||医薬品 医療関連（Health Care）|
|概要||事業概要 アムジェン(Amgen Inc.)はバイオテクノロジー会社である。同社は多様なヒト治療法を発見・開発・製造・提供する。同社はヒト治療事業を運営する。同社の製品ポートフォリオはNeulasta（ペグフィルグラスチム）、Aranesp（ダルベポエチンアルファ）・EPOGEN（エポエチンアルファ）等の赤血球産生促進剤（ESAs）、Sensipar/Mimpara（シナカルセット）、XGEVA（デノスマブ）、Prolia（デノスマブ）及びNEUPOGEN（フィルグラスチム）、並びにKYPROLIS（カルミゾミブ）、Vectibix（パニツムマブ）、Nplate（ロムリプスチム）、Repatha（エボロクマブ）、BLINCYTO（ブリナトモマブ）、IMLYGIC（タルミモジュラーラパーパープ）、Corlanor（イバブラジン）など他の市販製品を含む。同社は腫瘍/血液学、心臓血管疾患および神経科学の分野における重篤な疾患の治療のためのヒト治療法を提供し、反復性片頭痛治療用Erenumab、骨髄異形成症候群治療用Aranesp、急性リンパ芽球性白血病治療用BLINCYTOおよび転移性メラノーマ治療用IMLYGICを含むフェーズⅢの製品候補を提供する。 アムジェンはバイオ医薬品メ―カ―で、高度な細胞生物学と分子生物学に基づく治療薬の開発、製造、販売を展開する。特にがん、腎臓病、炎症、腫瘍学の分野での治療薬の開発に注力、製品は診療所、透析センタ―、病院に販売される。主要製品は、がん化学療法中の患者や透析患者向けの貧血症治療剤｢アラネスプ｣、白血球減少症治療剤｢ニュ―ラスタ｣など。 Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.|
|本社所在地||One Amgen Center Drive Thousand Oaks CA 91320-1799 USA|
|代表者氏名||Robert A. Bradway ロバート・A・ブラッドウェイ|
|代表者役職名||Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO）|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Amgen Inc. revenues increased 3% to $11.61B. Net income increased 9% to $4.61B. Revenues reflect Rest of the World segment increase of 9% to $2.51B Other segment increase of 18% to $591M. Net income benefited from Other decrease from $50M (expense) to $22M (income) Foreign currency contracts increase from $14M to $33M (income). Dividend per share increased from $2.30 to $2.64.|
New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps 2021/09/05 11:15:00 Amgen
Improvements Also Demonstrated in Lung Function and Nasal Polyp Symptoms Exploratory Analysis From NAVIGATOR Phase 3 Trial Presented at European Respiratory Society (ERS) International Congress 2021 THOUSAND OAKS, Calif. , Sept. 5, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data
Amgen to Present at the 16th Annual Citi BioPharma Conference 2021/09/03 20:00:00 Amgen
THOUSAND OAKS, Calif. , Sept. 3, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi''s 16th Annual BioPharma Conference at 1:25 p.m. ET on Wednesday, Sept. 8, 2021 . Murdo Gordon , executive vice president of Global Commercial Operations at Amgen will present at the conference.
Cell-Based Immunotherapy Market 2021 Emerging Developments, Rising Growth and Increasing Immense Opportunities Till 2028 | AbbVie Inc., Genentech USA, Inc., Amgen Inc, Bayer AG, Boehringer Ingelheim International GmbH & More 2021/09/03 16:18:45 OpenPR
The proposed Cell-Based Immunotherapy Market report will encompass all the qualitative & quantitative aspects including the market size, market estimates, growth rates & forecasts & hence will give you a holistic view of the market. The study also includes detailed
Global Microvillus Inclusion Disease Market Analysis, Scope and Forecast By 2021-2027. The IBI Updates I Top key players-3M, Amgen Inc., BSN Medical, ConvaTec Inc., Medtronic Plc., Smith & Nephew Plc., Laboratoris Sanifit S. & Others 2021/09/03 11:24:33 OpenPR
Infinity Business Insights'' research analyses market share, new innovations, and product pipeline analysis, as well as the impact of domestic and localised market competitors, growing revenue pockets, and changes in market laws. Microvillus inclusion disease is a very rare genetic
Bristol-Myers Misses Q1 Profit As Pandemic Hits Cancer Drugs Sales 2021/04/29 14:49:33 Benzinga
Bristol-Myers Squibb Co (NYSE: BMY ) joined other drugmakers in missing first-quarter earnings consensus due to a decline in medical visits and new diagnoses as COVID-19 cases surged at the start of the year. Today, Merck & Co Inc (NYSE: MRK ) reported Q1 earnings and sales that trailed Wall Street expectations, citing an early-in-the-year pandemic surge. Yesterday, Amgen Inc (NASDAQ: AMGN ) cited the pandemic effect in reporting a drop in its Q1 … Full story available on Benzinga.com
CDC Foundation Launches National Program to Educate Older Adults and Caregivers about Preventing Falls and Fall Injuries 2021/04/29 13:15:00 Benzinga
ATLANTA , April 29, 2021 /PRNewswire/ -- Today the CDC Foundation announced an important new initiative to prevent falls and fall injuries in older adults. Each year more than one in four older adults (age 65 and older) experience a fall, resulting in 3 million emergency department visits, 950,000 hospitalizations and 32,000 deaths. Many of these falls are preventable. Together, Amgen and the CDC Foundation, with leveraged technical resources from the Centers for Disease Control and Prevention (CDC), will support the project's development of user-friendly fall prevention resources for older adults and their caregivers. The five-year project will create digital resources to help older adults assess their risk of falls and develop a plan to mitigate that risk by speaking with their healthcare provider and caregiver. It will also include a communications campaign to educate and provide key tools for caregivers to help them talk to their loved ones about their risk for falls and ways to prevent falls and fall-related injuries. "Every second of every day an older adult falls in our country," said Debra Houry , MD, MPH, director of CDC's National Center for Injury Prevention and Control. "We know that falls are preventable and are not an inevitable part of aging.
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx 2021/04/29 12:15:49 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ: AXNX ) Boston Scientific Corporation (NYSE: BSX ) (reacted to first-quarter results) Celcuity Inc. (NASDAQ: CELC ) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Galectin Therapeutics Inc. (NASDAQ: GALT ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Integra LifeSciences Holdings Corporation (NASDAQ: IART ) (announced first-quarter results) Lantheus Holdings, Inc. (NASDAQ: LNTH ) MacroGenics, Inc. (NASDAQ: MGNX ) NuVasive, Inc. (NASDAQ: NUVA) PRA Health Sciences, Inc. (NASDAQ: PRAH ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Verastem, Inc. (NASDAQ: VSTM ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 28) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Decibel Therapeutics, Inc. (NASDAQ: DBTX ) IRadimed Corporation (NASDAQ: IRMD ) Lucira Health, Inc. (NASDAQ: LHDX ) Mesoblast Limited (NASDAQ: MESO ) Protara Therapeutics, Inc. (NASDAQ: TARA ) PTC Therapeutics, Inc. (NASDAQ: PTCT ) Stocks In Focus Adverum Shares Sink On Serious Adverse Event Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) announced a suspected unexpected serious adverse reaction of hypotony, which is clinically relevant decrease in ocular pressure, in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema.
Amgen Drops; FDA Urges Post-Marketing Study for Drug Candidate - TheStreet 2021/04/28 16:07:06 The Street
Amgen will test whether a lower dose of its Lumakras cancer-drug candidate works better for patients than the dose it has been studying.
Amgen Shares Drop On Light First Quarter Earnings Hit By Lower Prices 2021/04/28 12:38:29 Benzinga
Amgen Inc (NASDAQ: AMGN ) has a rough start this year after its Q1 March-quarter revenue slipped 4% from the year-ago quarter, while its earnings fell about 10%. Earnings: Even though unit volumes grew 4% in the quarter, the revenue disappointment was primarily tied to lower prices. Net sales prices fell 7%, year over year, the company said. Revenue was $5.9 billion, compared with the year-ago $6.2 billion, well below the consensus estimate of $6.25 billion. Amgen said new patient starts were hurt because the pandemic kept people from seeing doctors and getting diagnosed. Amgen’s most significant product, the autoimmune treatment Enbrel, suffered a 20% revenue … Full story available on Benzinga.com
Amgen's Bemarituzumab Scores Breakthrough Therapy Tag For Gastric, GEJ Cancers 2021/04/20 11:28:20 Benzinga
The FDA has granted Breakthrough Therapy Designation to Amgen Inc's (NASDAQ: AMGN ) bemarituzumab for patients with gastric and gastroesophageal (GEJ) adenocarcinoma. The designation covers bemarituzumab as first-line treatment of fibroblast growth factor receptor 2b, overexpressing and human epidermal growth factor receptor 2-negative, metastatic and locally advanced … Full story available on Benzinga.com
Citius Thrives in 2021 with Critical Care Solutions for ARDS Associated with COVID-19 2021/04/19 12:53:14 Benzinga
The following article is sponsored by Citius Pharmaceuticals, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Companies like Pfizer, Inc. ( NYSE: PFE ) , Syndax Pharmaceuticals ( NASDAQ: SNDX ), Merck & Co. ( NYSE: MRK ), and Amgen, Inc. (NASDAQ: AMGN ), among others, understand the importance of creating new, effective pharmaceutical critical care products for unmet needs. For example, long-term patients with central venous catheters (CVCs) for dialysis or cancer treatments are still at risk for complications related to bloodstream infections that might be fatal. This creates a new set of needs in order to have successful outcomes for these patients. Finding ways to avoid these complications can be lifesavers. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR ), a specialty pharmaceutical company dedicated to developing and commercializing novel critical care drug products, is addressing several of these unmet medical needs with cost-saving and cost-effective solutions with low-risk development pathways.
Is Silicon Valley Replacing Big Pharma In Neuroscience? 2021/04/06 12:54:07 Benzinga
The following article is sponsored by Mind Cure. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Over the past decade, big pharma has largely stepped away from the research and development of psychiatric drugs. This came after what was a fruitful period for the pharmaceutical industry during the 1990s and early 2000s. This renaissance was caused largely in part to the release of Eli Lilly And Co’s (NYSE: LLY ) Prozac, an antidepressant, in 1988. This SSRI (Selective Serotonin Reuptake Inhibitor) was seen as a major development in the field of neuroscience. Although since then, many major pharmaceutical companies have either devoted fewer resources to neurological research or have cut spending altogether. The industry has seen this with companies such as Pfizer Inc. (NYSE: PFE ), Amgen, Inc. (NASDAQ: AMGN ), AstraZeneca plc (NASDAQ: AZN ), Eli & Lily and Merck & Co., Inc. (NYSE: MRK ), among others.
The Latest Picks And Pans From Barron's: Barrick Gold, BioNTech, Facebook, WW And More 2021/04/04 14:09:33 Benzinga
This weekend's Barron's cover story discusses a beleaguered social media giant that is still a buy. Other featured articles share infrastructure picks, capital spending picks and a veteran fund manager's income picks. Also, see the prospects for an up-and-coming biotech, a gold rebound play, a personal services provider and more. Cover story " Like It or Not, Facebook Stock Is a Buy " by Max A. Cherney points out that social network Facebook, Inc. (NASDAQ: FB ) has been beat up by controversy, and yet users and advertisers keep showing up. See why Barron's believes investors now have a chance to buy a growth story on the cheap. Could the stock see a gain of 20% or more in the next year? Daren Fonda's " Stocks That Could Gain the Most From Biden's Infrastructure Plan " discusses how many infrastructure plays have already run up, yet there could be further gains if the market sees a bill inching toward passage. Featured picks run the gamut from Aecom (NYSE: ACM ) to Vulcan Materials Company (NYSE: VMC ).
関連キーワード （医薬品 米国株 アムジェン AMGN Amgen Inc.）